In-house Manufacturing Facility

Two years of gene therapy manufacturing expertise

First GCTP/cGMP/PICS GMP complied manufacturing facility with 200L bioreactor completed Mar 2017

The “Manufacturing License for Cell & Gene Therapy Products” applied July 2018

Benefits of in-house manufacturing

Highly cost efficient without the out-licensing to the major pharmaceutical company

More controllable and flexibility


Life Innovation Center based in Kanagawa

Current capacity: one 200L bioreactor

Plan to expand mfg process to 2nd and 3rd facility